November 05, 2025 a 09:00 am
COR: Analysts Ratings - Cencora, Inc.
Cencora, Inc., a renowned entity in pharmaceutical distribution, is under close observation by analysts, reflecting a stable outlook with a predominant stance of positive advisories. The consistent ratings suggest a balanced perception of its market potential and resilience amidst evolving industry dynamics. However, shifts in market sentiment over time indicate nuances in confidence levels.
Historical Stock Grades
Recent data indicates that Cencora, Inc.'s stocks have received varying levels of analyst ratings. As of November 2025, the stock's ratings feature a prominent number of "Buy" recommendations, indicating sustained interest among investors.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 10 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, there's been a discernible stabilization in analyst ratings for Cencora, Inc. The most reported rating is "Buy," signifying moderately strong market support.
- A marginal decline in "Strong Buy" ratings, indicating moderated aggressive confidence.
- Fluctuations in "Hold" ratings, with recent decreases suggesting reduced market hesitation.
- Overall analyst engagement has remained consistent, pointing to stable interest levels.
Percentage Trends
The proportional shift within analyst ratings highlights subtle sentiment changes. The "Buy" category has persisted as dominant, while "Hold" positions have recently decreased, pointing towards growing optimism.
- Strong Buy: Dropped from 5% to current levels.
- Buy: Consistently maintained at around 60-70% of recommendations.
- Hold: Downtrended recently, suggesting a move away from market caution.
Latest Analyst Recommendations
The latest recommendations reflect sustained levels of support, with maintained ratings levels. Analysts show confidence, as evident from the recent "Buy" and "Outperform" stances.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-30 | Outperform | Outperform | Mizuho |
| 2025-10-27 | Buy | Buy | UBS |
| 2025-10-16 | Outperform | Outperform | Mizuho |
| 2025-08-13 | Overweight | Overweight | Wells Fargo |
| 2025-07-16 | Equal Weight | Equal Weight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Significant shifts in recommendations are indicators of strategic re-evaluations. Recent changes have been minimal, showcasing stability in consensus.
| Date | New Recommendation | Previous Recommendation | Publisher |
|---|---|---|---|
| 2025-06-03 | Overweight | Equal Weight | Wells Fargo |
| 2022-10-11 | Buy | Neutral | B of A Securities |
| 2022-10-10 | Buy | Neutral | B of A Securities |
| 2022-07-11 | In Line | Outperform | Evercore ISI Group |
| 2022-07-10 | In Line | Outperform | Evercore ISI Group |
Interpretation
The steady trends and limited sentiment shifts suggest a solid market perception of Cencora, Inc. The slight decline in "Strong Buy" ratings, counterbalanced by consistent levels of "Buy" recommendations, indicates cautious optimism. A potential growing trust within the investor community, as seen in maintained recommendations amidst minimal downgrades. The stability of analyst opinions further underscores confidence in the company's strategic direction.
Conclusion
Overall, Cencora, Inc. presents a steady investment opportunity with moderate risk. The observed trends affirm a consistent trust level amongst analysts while pointing to growth potential in global markets. This balance of stable recommendations and significant interest highlights Cencora's ability to maintain investor confidence despite market fluctuations.